Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
7(100.0%)
7Total
Phase 1(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT03480646Phase 1Completed

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Role: lead

NCT02158858Phase 1Completed

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Role: lead

NCT05391022Phase 1Completed

Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

Role: lead

NCT01949883Phase 1Completed

A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma

Role: lead

NCT02157636Phase 1Completed

A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma

Role: lead

NCT03525795Phase 1Completed

ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors

Role: lead

NCT02395601Phase 1Completed

A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas

Role: lead

All 7 trials loaded